This exhibition continues the theme of "innovative technology, smart leadership in the future", focusing on digital medicine, high-end equipment, intelligent manufacturing, chronic disease management, elderly care and rehabilitation and other sub-sectors, and fully presents comprehensive and full-life cycle health services such as diagnosis and treatment, social security, chronic disease management, rehabilitation care, and focuses on leading products with advanced technology and quality services. Minkang has continuously deepened its vertical fields, increased its product research and development efforts with innovative technology, and served the health needs of different groups of people with innovative products, which were widely favored by the participants.

Among them, Jinkangzhun-blood glucose meter has become the focus of the whole field in the field promotion. Its gold test strip's nano-gold film technology and advanced FAD dehydrogenase technology can ensure the accuracy and stability of the test results. It should be emphasized that the HCT range of Jinkangzhun-blood glucose meter is 0-70%, which is the only home-use blood glucose detection product on the market to achieve such a wide range.

HCT refers to hematocrit, which is an important factor affecting blood viscosity. Blood glucose monitoring indicators are directly related to HCT. The HCT value of different people is different. The HCT value of ordinary people is between 35% and 50%. The range of newborn babies is wider, while the HCT value of anaemic people and pregnant women is usually lower. The HCT range of most blood glucose meters on the market is only applicable to ordinary people, while the HCT range of Jinkangzhun is 0-70%, which is applicable to anaemic people, pregnant women and other people, and can avoid the deviation of test results.

"Blood glucose/cholesterol/uric acid multi-function analyzer" is the first time to be displayed to the public. It is an advantageous product integrating three indicators detection. Its cholesterol detection adopts electrochemical technology, and the detection time is only 20 seconds, which is very convenient for the use of people with chronic diseases.

Before the opening of the exhibition, Minkang just signed a cooperation agreement with the University of Science and Technology of China to jointly launch the research and development of the artificial pancreas project, marking that Minkang has entered a new stage of development from chronic disease detection to data analysis to the implementation of the ecological closed-loop of chronic disease management, and the company will also continue to move from "diabetes comprehensive service" to "diabetes comprehensive solution".

In April next year, Minkang will meet with you at CMEF Shanghai.